Efficacy and safety of the losartan-hydrochlorothiazide combination tablet in patients with hypertension uncontrolled by angiotensin II receptor antagonist therapy: The Aichi research on combination therapy for hypertension (ARCH) study

Internal Medicine

Volumn 51, Issue 10, 2012, Pages 1167-1175

  Maeda, Kengo ^a   Adachi, Masayoshi ^b   Kinoshita, Atsushi ^c   Koh, Naoki ^d   Miura, Yoshitaka ^e   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Adachi Clinic Internal Medicine and Cardiovascular Medicine   (Japan)

^c Kinoshita Clinic   (Japan)

^d Koh Internal Medicine Clinic   (Japan)

^e Miura Internal Medicine Clinic   (Japan)

Author keywords

Angiotensin II receptor antagonist; Antihypertensive agent; Hydrochlorothiazide; Hypertension; Losartan

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CHLORIDE; CHOLESTEROL; CREATININE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; LACTATE DEHYDROGENASE; POTASSIUM; SODIUM;

AGED; ALCOHOL CONSUMPTION; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BRAIN INFARCTION; CLINICAL TRIAL; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENDER; HEMATOCRIT; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPEN STUDY; PROSPECTIVE STUDY; PULSE RATE; RASH; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; JAPAN; LOSARTAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84861728831     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.6297     Document Type: Article

References (16)

1. Intersalt Cooperative Research Group. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. BMJ 297: 319-328, 1988.
2. Ohta Y, Tsuchihashi T, Onaka U, Eto K, Ueno M. Usefulness of the α1-blocker doxazosin as a third-line antihypertensive drug. Hypertens Res 30: 301-306, 2007.
3. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 358: 1305-1315, 2001.
4. Manolis AJ, Grossman E, Jelakovic B, et al. Losartan Trial Investigators. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Clin Ther 22: 1186-1203, 2000.
5. Chan JCN, Critchley JAJH, Lappe JT, et al. Randomised, doubleblind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension. J Hum Hypertens 9: 765-771, 1995.
6. Dahlöf B, Keller Se, Makris L, Goldberg AI, Sweet CS, Lim NY. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 8: 578-583, 1995.
7. Tikkanen I, Omvik P, Jensen HA. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 13: 1343-1351, 1995.
8. Mallion JM, Bradstreet DC, Makris L, et al. Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension. J Hypertens Suppl 13: S35-S41, 1995.
9. Dahlöf B, Devereux RB, Kjeldsen SE, et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359: 995-1003, 2002.
10. Dahlöf B, Sever PS, Poulter NR, et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet 366: 895-906, 2005.
11. Luft FC, Weinberger MH, Fineberg NS, Miller JZ, Grim CE. Effects of age on renal sodium homeostasis and its relevance to sodium sensitivity. Am J Med 82: 9-15, 1987.
12. Staessen JA, Celis H, Fagard R. The epidemiology of the association between hypertension and menopause. J Hum Hypertens 12: 587-592, 1998.
13. Luoto R, Sharrett AR, Schreiner P, Sorlie PD, Arnett D, Ephross S. Blood pressure and menopausal transition: the Atherosclerosis Risk in Communities study (1987-95). J Hypertens 18: 27-33, 2000.
14. Nakamura K, Okamura T, Hayakawa T, et al.; NIPPON DATA 90 Research Group. The proportion of individuals with alcohol-induced hypertension among total hypertensives in a general Japanese population: NIPPON DATA 90. Hypertens Res 30: 663-668, 2007.
15. Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects of alcohol reduction on blood pressure: a metaanalysis of randomized controlled trials. Hypertension 38: 1112-1117, 2001.
16. Puddey IB, Beilin LJ, Vandongen R. Regular alcohol use raises blood pressure in treated hypertensive subjects. A randomised controlled trial. Lancet 1: 647-651, 1987.